GG
ACAD icon

Gofen & Glossberg’s Acadia Pharmaceuticals ACAD Stock Holding History

Gofen & Glossberg’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,155
Closed -$164K – 445
2018
Q4 		$164K Hold
10,155
– – 0.01% 406
2018
Q3 		$211K Buy
+10,155
New +$160K 0.01% 426

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Gofen & Glossberg's ACAD Position: Q1 2019 in Review

Gofen & Glossberg sold out of Acadia Pharmaceuticals (ACAD) in Q1 2019, closing a stake of 10,155 shares — an estimated $164K sold.

Gofen & Glossberg first reported a position in ACAD in Q3 2018 and held it in 2 quarters. The position peaked at $211K in Q3 2018. 199 funds tracked by Wall St. Rank hold ACAD as of Q1 2019.

  • Gofen & Glossberg reported no remaining Acadia Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Gofen & Glossberg sold 10,155 Acadia Pharmaceuticals shares in Q1 2019, an estimated $164K.
  • Gofen & Glossberg first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Gofen & Glossberg's Acadia Pharmaceuticals position peaked at $211K in Q3 2018.
  • 199 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2019.

Based on Gofen & Glossberg's 13F filing for Q1 2019, filed 11 Apr 2019.